SUCRALFATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for sucralfate and what is the scope of patent protection?
Sucralfate
is the generic ingredient in two branded drugs marketed by Abbvie, Abon Pharms Llc, Amneal, Hikma, Mylan, Pd Partners, Strides Pharma, Vistapharm Llc, Amneal Pharms, Nostrum Labs Inc, Teva, and Zydus Lifesciences, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.There are fourteen drug master file entries for sucralfate. Forty-one suppliers are listed for this compound.
Summary for SUCRALFATE
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 12 |
NDAs: | 13 |
Drug Master File Entries: | 14 |
Finished Product Suppliers / Packagers: | 41 |
Clinical Trials: | 25 |
Drug Prices: | Drug price trends for SUCRALFATE |
Drug Sales Revenues: | Drug sales revenues for SUCRALFATE |
What excipients (inactive ingredients) are in SUCRALFATE? | SUCRALFATE excipients list |
DailyMed Link: | SUCRALFATE at DailyMed |
Recent Clinical Trials for SUCRALFATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cheng-Kung University Hospital | N/A |
National Cheng-Kung University Hospital | Phase 1 |
Memorial Sloan Kettering Cancer Center | Phase 2 |
Pharmacology for SUCRALFATE
Drug Class | Aluminum Complex |
Medical Subject Heading (MeSH) Categories for SUCRALFATE
Anatomical Therapeutic Chemical (ATC) Classes for SUCRALFATE
US Patents and Regulatory Information for SUCRALFATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | CARAFATE | sucralfate | TABLET;ORAL | 018333-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Nostrum Labs Inc | SUCRALFATE | sucralfate | TABLET;ORAL | 074415-001 | Jun 8, 1998 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Zydus Lifesciences | SUCRALFATE | sucralfate | TABLET;ORAL | 215705-001 | May 3, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Vistapharm Llc | SUCRALFATE | sucralfate | SUSPENSION;ORAL | 211884-001 | Mar 15, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Abon Pharms Llc | SUCRALFATE | sucralfate | SUSPENSION;ORAL | 216726-001 | Mar 21, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SUCRALFATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | CARAFATE | sucralfate | TABLET;ORAL | 018333-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.